Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
- Associated Therapies
- -
Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Target Recruit Count
- 5
- Registration Number
- NCT02273700
- Locations
- 🇫🇷
CHRU de Nîmes - Hôpital Universitaire Carémeau, Nîmes Cedex 09, France
Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Hanyang University Seoul Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT02271399
- Locations
- 🇰🇷
Department of Orthopaedic Surgery, Hanyang University, College of Medicine, Seoul, Korea, Republic of
Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
- Conditions
- Interventions
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Ottawa Heart Institute Research Corporation
- Target Recruit Count
- 1284
- Registration Number
- NCT02168829
- Locations
- 🇩🇪
Segeberger Liniken, Bad Segeberg, Schleswig-Holstein, Germany
🇩🇪UKSH Lubeck, Lubeck, Schleswig-Holstein, Germany
🇦🇺Heart Rhythm Clinic, Nedlands, Western Australia, Australia
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 179
- Registration Number
- NCT02164578
- Locations
- 🇩🇪
GWT-TUD GmbH / Studienzentrum Hanefeld, Dresden, Germany
🇩🇪Krankenhaus Dresden-Friedrichstadt, Dresden, Sachsen, Germany
🇩🇪Gemeinschaftspraxis Dr. Schaper/ Dr. Faulmann, Dresden, Germany
Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 51
- Registration Number
- NCT02161965
- Locations
- 🇫🇷
University Hospital Angers, Angers, France
Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 12
- Registration Number
- NCT02128841
- Locations
- 🇨🇭
Dep. of Cardiovascular Surgery, Berne University Hospital, Bern, Switzerland
Rivaroxaban Anticoagulation for Superficial Vein Thrombosis
- Conditions
- Interventions
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 85
- Registration Number
- NCT02123524
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦Montreal General Hospital, Montreal, Quebec, Canada
🇨🇦McMaster Hospital, Hamilton, Ontario, Canada
Rivaroxaban for Antiphospholipid Antibody Syndrome
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- St. Joseph's Healthcare Hamilton
- Target Recruit Count
- 81
- Registration Number
- NCT02116036
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦Hamilton General Hospital, Hamilton, Ontario, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.
- Conditions
- Interventions
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2014-03-14
- Lead Sponsor
- Centre of Postgraduate Medical Education
- Target Recruit Count
- 60
- Registration Number
- NCT02085824
- Locations
- 🇵🇱
Prof. A. Gruca Teaching Hospital, The Medical Centre of Postgraduate Education, Otwock, Woj. Mazowieckie, Poland
The Effect of Rivaroxaban in Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 14
- Registration Number
- NCT02072668
- Locations
- 🇺🇸
University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.